All Stories

  1. The Role of IL-17 in Papulopustular Rosacea and Future Directions
  2. Canadian Patients’ Preferences in Topical Psoriasis Care: Insights From the PROPEL Surveys
  3. Psoriasis patients’ preference for an aerosol foam topical formulation
  4. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
  5. Survival of the fittest
  6. Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
  7. Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice
  8. A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults
  9. Acitretin use in Dermatology.
  10. Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition
  11. Undergraduate Dermatology Education in Canada: A National Survey
  12. Biosimilars for psoriasis: clinical studies to determine similarity
  13. An Open Letter to Health Canada
  14. Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice
  15. Review of Systemic Treatment Options for Adult Atopic Dermatitis
  16. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
  17. Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
  18. 2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009
  19. Acral Hemorrhagic Darier’s Disease
  20. Psoronychomycosis: A New Term for an Old Problem
  21. Biosimilars for psoriasis: preclinical analytical assessment to determine similarity
  22. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
  23. Non-melanoma Skin Cancer in Canada Chapter 1: Introduction to the Guidelines
  24. Non-melanoma Skin Cancer in Canada Chapter 2: Primary Prevention of Non-melanoma Skin Cancer
  25. Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses
  26. Non-melanoma Skin Cancer in Canada Chapter 4: Management of Basal Cell Carcinoma
  27. Non-melanoma Skin Cancer in Canada Chapter 5: Management of Squamous Cell Carcinoma
  28. Paradoxical, Cupping-Induced Localized Psoriasis: A Koebner Phenomenon
  29. Public Engagement with Dermatology Contents on Facebook
  30. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab
  31. Think beyond the Skin
  32. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)
  33. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin
  34. Use of Facebook as a Tool for Knowledge Dissemination in Dermatology
  35. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
  36. Interleukin 17A: Toward a new understanding of psoriasis pathogenesis
  37. A Consensus on Acne Management Focused on Specific Patient Features
  38. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
  39. One-Year, Multicenter, Open-Label, Single-Arm Study Evaluating the Safety and Effectiveness of Etanercept for the Treatment of Moderate-to-Severe Plaque Psoriasis in a Canadian Population
  40. Sulfa or Sulfur? Clearing Things up
  41. Etanercept Improves Quality of Life Outcomes and Treatment Satisfaction in Patients with Moderate to Severe Plaque Psoriasis in Clinical Practice
  42. Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis
  43. Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis
  44. Comparison of Dermatologists' and Nondermatologists' Diagnostic Accuracy for Malignant Melanoma
  45. Erythema ab igne caused by laptop computer gaming - a case report
  46. Double-Blinded, Vehicle-Controlled Proof of Concept Study to Investigate the Recurrence of Inflammatory and Noninflammatory Acne Lesions Using Tretinoin Gel (Microsphere) 0.04% in Male Patients after Oral Isotretinoin Use
  47. Topical Psoriasis Therapy in the Age of Biologics: Evidence-Based Treatment Recommendations
  48. Canadian Guidelines for the Management of Plaque Psoriasis: Overview
  49. Adalimumab for Treatment of Moderate to Severe Chronic Plaque Psoriasis of the Hands and Feet
  50. Systemic Role for Vitamin D in the Treatment of Psoriasis and Metabolic Syndrome
  51. Gourmet Clinical Pearls
  52. Quality of life in plaque psoriasis patients treated with voclosporin: a Canadian phase III, randomized, multicenter, double-blind, placebo-controlled study
  53. Drug-Induced Lichenoid Dermatitis with Histopathologic Features of Mycosis Fungoides in a Patient with Psoriasis
  54. Are Excipients Really Inert Ingredients? A Review of Adverse Reactions to Excipients in Oral Dermatologic Medications in Canada
  55. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis
  56. Efficacy Outcomes in Patients Using Alefacept in the AWARE Study
  57. Adalimumab in the Treatment of Psoriasis: Pooled Efficacy and Safety Results from Three Pivotal Studies
  58. Nail Psoriasis and Biologics
  59. Occurrence of Plantar Pustular Psoriasis during Treatment with Infliximab
  60. Practical Understanding of Mean Percent Psoriasis Area and Severity Index Reduction for Biologics
  61. Are All Seborrheic Keratoses Benign? Review of the Typical Lesion and Its Variants
  62. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
  63. Pimecrolimus cream 1% in the long-term management of adult atopic dermatitis: prevention of flare progression. A randomized controlled trial
  64. Psoriasis of the nail: Anatomy, pathology, clinical presentation, and a review of the literature on therapy
  65. Miliarial Gout (A New Entity)
  66. Multitherapy Approach to Onychomycosis Therapy
  67. Prevalence and Epidemiology of Onychomycosis
  68. Cutaneous Reaction to Drugs Used for Erectile Dysfunction: Case Report and Review of the Literature
  69. Use of Calcipotriene Cream (Dovonex?? Cream) Following Acute Treatment of Psoriasis Vulgaris with the Calcipotriene/Betamethasone Dipropionate Two-Compound Product (Taclonex??)
  70. Antihistamines in the Treatment of Atopic Dermatitis
  71. Pharmacology of TNF inhibitors